Literature DB >> 26178796

Improving the anti-inflammatory effect of serum eye drops using allogeneic serum permissive for regulatory T cell induction.

Per-Anton Stenwall1, Marcus Bergström1, Peter Seiron1, Felix Sellberg1, Tobias Olsson1, Folke Knutson2, David Berglund1.   

Abstract

PURPOSE: To investigate the cytokine composition and anti-inflammatory effects of allogeneic serum preparations for improved use as serum eye drops.
METHODS: Serum of 15 healthy blood donors was extensively screened for cytokines, including IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-13, IL-15, 1L-17A, E and F, IL-21, IL-22, IL-23, IL-27, IL-28A, IL-31, IL-33, granulocyte macrophage colony-stimulating factor (GM-CSF), chemokine ligand 20 (CCL20), tumour necrosis factor (TNF)-α and TNF-β, interferon (IFN)-γ and transforming growth factor (TGF)-β. The levels of cytokines were assessed before and after heat-induced inactivation. Individual serum preparations were tested for their anti-inflammatory effect using an in vitro test to differentiate effector T lymphocytes into anti-inflammatory regulatory T cells.
RESULTS: The anti-inflammatory cytokine TGF-β was readily detected in the serum of all blood donors and was only modestly affected by heat-induced inactivation. Serum containing high amounts of TGF-β was more effective at inducing anti-inflammatory regulatory T cells. The serum of one healthy blood donor displayed high levels of inflammatory cytokines.
CONCLUSION: We propose that serum used as eye drops is screened for its cytokine content, making it possible to correlate the composition to the clinical outcome. Based on the findings in this study, tailored serum eye drops produced from allogeneic donors may provide increased anti-inflammatory effects. This may be superior to autologous serum eye drops, which in many cases are retrieved from patients with inflammatory diseases.
© 2015 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  TGF-beta; allogeneic serum eye drops; cytokines; dry eye; regulatory T cells

Mesh:

Substances:

Year:  2015        PMID: 26178796     DOI: 10.1111/aos.12801

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  14 in total

1.  Amniotic membrane extract eye drops for ocular surface diseases: use and clinical outcome in real-world practice.

Authors:  Noelia Sabater-Cruz; Marc Figueras-Roca; Miriam Ferrán-Fuertes; Elba Agustí; Eva M Martínez-Conesa; María Luisa Pérez-Rodríguez; Anna Vilarrodona; Ricardo P Casaroli-Marano
Journal:  Int Ophthalmol       Date:  2021-04-17       Impact factor: 2.031

Review 2.  Regenerative Therapies in Dry Eye Disease: From Growth Factors to Cell Therapy.

Authors:  Antonio J Villatoro; Viviana Fernández; Silvia Claros; Cristina Alcoholado; Manuel Cifuentes; Jesús Merayo-Lloves; José A Andrades; José Becerra
Journal:  Int J Mol Sci       Date:  2017-10-28       Impact factor: 5.923

3.  Serum components and clinical efficacies of autologous serum eye drops in dry eye patients with active and inactive Sjogren syndrome.

Authors:  I-Hsin Ma; Lily Wei Chen; Wen-Hui Tu; Chia-Ju Lu; Chien-Jung Huang; Wei-Li Chen
Journal:  Taiwan J Ophthalmol       Date:  2017 Oct-Dec

4.  Comparison of corneal epitheliotrophic capacities among human platelet lysates and other blood derivatives.

Authors:  Chien-Jung Huang; Yi-Chen Sun; Karen Christopher; Amy Shih-I Pai; Chia-Ju Lu; Fung-Rong Hu; Szu-Yuan Lin; Wei-Li Chen
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

Review 5.  Application of Novel Drugs for Corneal Cell Regeneration.

Authors:  Sang Beom Han; Yu-Chi Liu; Karim Mohamed-Noriega; Jodhbir S Mehta
Journal:  J Ophthalmol       Date:  2018-05-02       Impact factor: 1.909

Review 6.  Blood-Based Treatments for Severe Dry Eye Disease: The Need of a Consensus.

Authors:  Federico Bernabei; Matilde Roda; Marina Buzzi; Marco Pellegrini; Giuseppe Giannaccare; Piera Versura
Journal:  J Clin Med       Date:  2019-09-17       Impact factor: 4.241

7.  Hyaluronic Acid as an Alternative to Autologous Human Serum Eye Drops: Initial Clinical Results with High-Molecular-Weight Hyaluronic Acid Eye Drops.

Authors:  Ria Beck; Oliver Stachs; Anita Koschmieder; Wolfgang G K Mueller-Lierheim; Sabine Peschel; Gysbert-Botho van Setten
Journal:  Case Rep Ophthalmol       Date:  2019-08-06

8.  The corneal epitheliotrophic abilities of lyophilized powder form human platelet lysates.

Authors:  Lily Wei Chen; Chien-Jung Huang; Wen-Hui Tu; Chia-Ju Lu; Yi-Chen Sun; Szu-Yuan Lin; Wei-Li Chen
Journal:  PLoS One       Date:  2018-03-16       Impact factor: 3.240

9.  Cord Blood Platelet Rich Plasma Derivatives for Clinical Applications in Non-transfusion Medicine.

Authors:  Dinara Samarkanova; Steven Cox; Diana Hernandez; Luciano Rodriguez; Ricardo P Casaroli-Marano; Alejandro Madrigal; Sergio Querol
Journal:  Front Immunol       Date:  2020-05-27       Impact factor: 7.561

10.  Development and Optimization of Freeze-Dried Eye Drops Derived From Plasma Rich in Growth Factors Technology.

Authors:  Eduardo Anitua; María de la Fuente; Ignacio Alcalde; Cristina Sanchez; Jesús Merayo-Lloves; Francisco Muruzabal
Journal:  Transl Vis Sci Technol       Date:  2020-06-25       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.